Suppr超能文献

前蛋白转化酶枯草杆菌蛋白酶/kexin 9型在大鼠心肌梗死急性期的表达短暂上调。

Proprotein convertase subtilisin/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat.

作者信息

Zhang Yan, Liu Jun, Li Sha, Xu Rui-Xia, Sun Jing, Tang Yue, Li Jian-Jun

机构信息

Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing 100037, China.

出版信息

BMC Cardiovasc Disord. 2014 Dec 17;14:192. doi: 10.1186/1471-2261-14-192.

Abstract

BACKGROUND

The proprotein convertase subtilisin/kexin type 9 (PCSK9) has been confirmed as a major factor regulating cholesterol homeostasis and has low-density lipoprotein receptor (LDLR) independent effects. In addition, the pathogenesis of acute myocardial infarction (AMI) involves lipids alteration and other acute phase responses. It remains unknown whether the PCSK9 expression is influenced by the impact of AMI. The present study aimed to investigate the changes of PCSK9 concentration using AMI rat model.

METHODS

AMI (n = 6-8 at each time point) or sham operated (n = 6) adult male rats model were used. Whole blood and liver tissue were collected at 1, 3, 6, 9, 12, 24, 48, and 96 hour (h) post infarction. The plasma PCSK9 concentration was measured by ELISA and lipid profiles were measured by enzymatic assay. The liver mRNA levels of PCSK9, LDLR, sterol response element binding protein-2 (SREBP-2) and hepatocyte nuclear factor 1α (HNF1α) were measured by quantitative real-time PCR.

RESULTS

The plasma PCSK9 concentration was increased from 12 h to 96 h (P < 0.05 vs. control). Paralleled with the enhanced plasma PCSK9 concentration, the hepatic PCSK9 mRNA expression was up-regulated by 2.2-fold at 12 h and 4.1-fold at 24 h. Hepatic mRNA levels of LDLR, SREBP-2 and HNF1α were all increased and lipid profiles underwent great changes at this acute period.

CONCLUSIONS

We firstly demonstrated that PCSK9 was transiently up-regulated in the acute period of AMI, which is also driven by transcriptional factors, SREBP-2 and HNF1α, suggesting that the role of PCSK9 in myocardial injury may be needed further study.

摘要

背景

前蛋白转化酶枯草溶菌素/kexin 9型(PCSK9)已被确认为调节胆固醇稳态的主要因素,且具有低密度脂蛋白受体(LDLR)非依赖效应。此外,急性心肌梗死(AMI)的发病机制涉及脂质改变和其他急性期反应。PCSK9表达是否受AMI影响仍不清楚。本研究旨在利用AMI大鼠模型研究PCSK9浓度的变化。

方法

采用AMI(每个时间点n = 6 - 8)或假手术(n = 6)成年雄性大鼠模型。在梗死术后1、3、6、9、12、24、48和96小时(h)采集全血和肝组织。通过酶联免疫吸附测定(ELISA)法测定血浆PCSK9浓度,通过酶法测定血脂谱。通过定量实时聚合酶链反应(PCR)法测定肝脏中PCSK9、LDLR、固醇调节元件结合蛋白2(SREBP - 2)和肝细胞核因子1α(HNF1α)的mRNA水平。

结果

血浆PCSK9浓度从12小时至96小时升高(与对照组相比,P < 0.05)。与血浆PCSK9浓度升高相平行,肝脏PCSK9 mRNA表达在12小时上调2.2倍,在24小时上调4.1倍。在此急性期,肝脏中LDLR、SREBP - 2和HNF1α的mRNA水平均升高,血脂谱发生了很大变化。

结论

我们首次证明,PCSK9在AMI急性期短暂上调,且由转录因子SREBP - 2和HNF1α驱动,提示PCSK9在心肌损伤中的作用可能需要进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0624/4279995/212802abedd1/12872_2014_834_Fig1_HTML.jpg

相似文献

5
Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
J Am Coll Cardiol. 2013 Oct 15;62(16):1401-8. doi: 10.1016/j.jacc.2013.07.056. Epub 2013 Aug 21.
6
Chitosan oligosaccharides enhance lipid droplets via down-regulation of PCSK9 gene expression in HepG2 cells.
Exp Cell Res. 2018 May 15;366(2):152-160. doi: 10.1016/j.yexcr.2018.03.013. Epub 2018 Mar 14.

引用本文的文献

1
Impact of In-Hospital PCSK9 Inhibition on Myocardial Inflammation After Myocardial Infarction: A Randomized Clinical Trial.
JACC Basic Transl Sci. 2025 Jun;10(6):709-720. doi: 10.1016/j.jacbts.2025.03.010. Epub 2025 May 28.
5
The role of PCSK9 in heart failure and other cardiovascular diseases-mechanisms of action beyond its effect on LDL cholesterol.
Heart Fail Rev. 2024 Sep;29(5):917-937. doi: 10.1007/s10741-024-10409-7. Epub 2024 Jun 18.
6
Maternal Obesity Modulates Cord Blood Concentrations of Proprotein Convertase Subtilisin/Kexin-type 9 Levels.
J Endocr Soc. 2024 Feb 20;8(4):bvae031. doi: 10.1210/jendso/bvae031. eCollection 2024 Feb 19.
7
ANMCO position paper on the management of hypercholesterolaemia in patients with acute coronary syndrome.
Eur Heart J Suppl. 2023 May 18;25(Suppl D):D312-D322. doi: 10.1093/eurheartjsupp/suad100. eCollection 2023 May.

本文引用的文献

1
The relationship between high-sensitive troponin T, neutrophil lymphocyte ratio and SYNTAX Score.
Scand J Clin Lab Invest. 2014 Mar;74(2):108-15. doi: 10.3109/00365513.2013.860619. Epub 2013 Dec 5.
3
Short-term impact of low-dose atorvastatin on serum proprotein convertase subtilisin/kexin type 9.
Clin Drug Investig. 2013 Dec;33(12):877-83. doi: 10.1007/s40261-013-0129-2.
5
Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
J Am Coll Cardiol. 2013 Oct 15;62(16):1401-8. doi: 10.1016/j.jacc.2013.07.056. Epub 2013 Aug 21.
6
Plasma PCSK9 is a late biomarker of severity in patients with severe trauma injury.
J Clin Endocrinol Metab. 2013 Apr;98(4):E732-6. doi: 10.1210/jc.2012-4236. Epub 2013 Feb 28.
8
Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication.
J Clin Endocrinol Metab. 2012 Nov;97(11):3956-64. doi: 10.1210/jc.2012-1563. Epub 2012 Aug 14.
9
The modification of serum lipids after acute coronary syndrome and importance in clinical practice.
Curr Cardiol Rev. 2011 Nov;7(4):272-6. doi: 10.2174/157340311799960690.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验